FY2025 Earnings Estimate for QNRX Issued By Zacks Small Cap

Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) – Equities researchers at Zacks Small Cap upped their FY2025 earnings estimates for shares of Quoin Pharmaceuticals in a report issued on Monday, March 17th. Zacks Small Cap analyst M. Marin now anticipates that the company will post earnings per share of ($0.44) for the year, up from their previous estimate of ($2.00). The consensus estimate for Quoin Pharmaceuticals’ current full-year earnings is ($2.05) per share.

Quoin Pharmaceuticals Stock Up 3.4 %

QNRX stock opened at $0.30 on Thursday. The firm has a market capitalization of $1.52 million, a PE ratio of -0.07 and a beta of 1.82. The stock has a 50-day simple moving average of $0.36 and a two-hundred day simple moving average of $0.55. Quoin Pharmaceuticals has a twelve month low of $0.27 and a twelve month high of $1.57.

Quoin Pharmaceuticals (NASDAQ:QNRX) last released its earnings results on Thursday, March 13th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.50) by $0.15.

Insider Activity at Quoin Pharmaceuticals

In related news, CFO Gordon Dunn acquired 122,221 shares of Quoin Pharmaceuticals stock in a transaction on Monday, December 23rd. The shares were acquired at an average cost of $0.45 per share, with a total value of $54,999.45. Following the transaction, the chief financial officer now owns 151,077 shares in the company, valued at $67,984.65. This trade represents a 423.55 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, COO Denise P. Carter purchased 555,556 shares of the firm’s stock in a transaction that occurred on Monday, December 23rd. The stock was bought at an average cost of $0.45 per share, with a total value of $250,000.20. Following the completion of the purchase, the chief operating officer now owns 602,648 shares of the company’s stock, valued at $271,191.60. This represents a 1,179.72 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last three months, insiders have bought 777,777 shares of company stock valued at $350,000. Corporate insiders own 3.70% of the company’s stock.

Institutional Investors Weigh In On Quoin Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in the stock. Altium Capital Management LLC purchased a new position in shares of Quoin Pharmaceuticals during the fourth quarter valued at approximately $184,000. Renaissance Technologies LLC grew its stake in Quoin Pharmaceuticals by 244.1% during the fourth quarter. Renaissance Technologies LLC now owns 133,122 shares of the company’s stock valued at $87,000 after acquiring an additional 94,431 shares in the last quarter. Boothbay Fund Management LLC purchased a new stake in shares of Quoin Pharmaceuticals in the fourth quarter worth about $53,000. Finally, Apollon Wealth Management LLC bought a new stake in Quoin Pharmaceuticals in the fourth quarter worth $52,000. 8.63% of the stock is owned by institutional investors.

Quoin Pharmaceuticals Company Profile

Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma.